Physician profile
Sharon Whyte
NPI 1669924585
$586.89
in general payments reported to CMS, 2019-2025
15 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.02 · 2022: $97.96 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $438.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $98.83 | 2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.96 | 2022 | |
| Lilly USA, LLC | $57.43 | 2025 | Zepbound, Mounjaro |
| Dexcom, INC. | $51.05 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.02 | 2021 | |
| Abbvie INC. | $33.12 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $29.40 | 2025 | Breztri, Farxiga |
| Hologic Sales and Service, LLC | $24.55 | 2025 | Aptima |
| Lundbeck LLC | $23.58 | 2025 | Rexulti |
| Abbott Laboratories | $23.57 | 2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $23.48 | 2025 | Auvelity |
| Tonix Medicines, INC. | $20.67 | 2025 | Tonmya |
| Corcept Therapeutics | $18.98 | 2025 | Korlym |
| Exact Sciences Corporation | $18.97 | 2025 | The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $15.28 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Whyte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.